(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 May 2022 (27.05.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/109555 A1

(51) International Patent Classification:
A61K 9/10 (2006.01) *A61P 31/18* (2006.01)
A61K 31/505 (2006.01) *A61K 9/50* (2006.01)
A61K 38/47 (2006.01) *A61K 47/10* (2017.01)

(21) International Application Number:
PCT/US2021/072453

(22) International Filing Date:
17 November 2021 (17.11.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/114,997 17 November 2020 (17.11.2020) US

(71) Applicant: **JANSSEN SCIENCES IRELAND UNLIMITED COMPANY** [IE/IE]; Barnahely Ringaskiddy, County Cork (IE).

(72) Inventors: **VESOLE, Steven M.**; c/o: JANSSEN RESEARCH & DEVELOPMENT, LLC, 920 US Route 202, P.O. Box 300, Raritan, New Jersey 08869 (US). **KRAUS, Guenter Karl Wilhelm**; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **CRAUWELS, Herta Maria Ludovica**; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **HOLM, René**; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **NIEMEIJER, Nico Rudolph**; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **VERVOORT, Iwan Caroline F.**; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE).

(74) Agent: **SHIRTZ, Joseph F.** et al.; JOHNSON & JOHNSON, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2022/109555 A1

(54) Title: TREATMENT OR PREVENTION OF HIV INFECTION

(57) Abstract: The present invention relates to the treatment or prevention of HIV infection using rilpivirine or a pharmaceutically acceptable salt thereof in the form of micro- or nanoparticles in suspension in combination with a hyaluronidase. The present invention also relates to rilpivirine or a pharmaceutically acceptable salt thereof in the form of micro- or nanoparticles in suspension.